Cargando…

Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors

PURPOSE: Poly(ADP-ribose) polymerase-1 (PARP-1) is a nuclear enzyme important in DNA repair. PARP-1 activation at points of DNA strand break results in poly(ADP-ribose) polymer formation, opening the DNA structure, and allowing access of other repair enzymes. CEP-9722 inhibits PARP-1 and PARP-2 and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Plummer, Ruth, Stephens, Peter, Aissat-Daudigny, Louiza, Cambois, Anne, Moachon, Gilbert, Brown, Peter D., Campone, Mario
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4112042/ https://www.ncbi.nlm.nih.gov/pubmed/24880570 http://dx.doi.org/10.1007/s00280-014-2486-9

Ejemplares similares

The combination therapy of isomucronulatol 7-O-beta-glucoside (IMG) and CEP-9722 targeting ferroptosis-related biomarkers in non-small cell lung cancer (NSCLC)
por: Cui, Xiaofei, et al.
Publicado: (2023)

Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing’s Sarcoma
por: Gill, Sonja J., et al.
Publicado: (2015)

SPDR-05 PARP INHIBITORS RESTORE TEMOZOLOMIDE SENSITIVITY IN MSH6-DEFICIENT TEMOZOLOMIDE-RESISTANT GLIOBLASTOMA CELLS
por: Higuchi, Fumi, et al.
Publicado: (2019)

Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors
por: Li, Huiping, et al.
Publicado: (2020)

First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor
por: Plummer, Ruth, et al.
Publicado: (2020)

PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers
por: Teyssonneau, Diego, et al.
Publicado: (2022)

Phase II study of temozolomide monotherapy in patients with extrapulmonary neuroendocrine carcinoma
por: Kobayashi, Noritoshi, et al.
Publicado: (2021)

Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study
por: Isakoff, S J, et al.
Publicado: (2014)

Cep70 and Cep131 contribute to ciliogenesis in zebrafish embryos
por: Wilkinson, Christopher J, et al.
Publicado: (2009)

Cep63 and Cep152 Cooperate to Ensure Centriole Duplication
por: Brown, Nicola J., et al.
Publicado: (2013)

Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy
por: Chen, Zheling, et al.
Publicado: (2021)

Methadone Potentiates the Cytotoxicity of Temozolomide by Impairing Calcium Homeostasis and Dysregulation of PARP in Glioblastoma Cells
por: Honc, Ondrej, et al.
Publicado: (2023)

PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy
por: Bian, X, et al.
Publicado: (2018)

Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies
por: Brada, M, et al.
Publicado: (1999)

Expanding the Use of PARP Inhibitors as Monotherapy and in Combination in Triple-Negative Breast Cancer
por: Yordanova, Mariya, et al.
Publicado: (2021)

THU520 Successful Treatment Of Ectopic ACTH From Metastatic Gastrinoma With Temozolomide Monotherapy
por: Syeda, Asma, et al.
Publicado: (2023)

The PARP1 Inhibitor Niraparib Represses DNA Damage Repair and Synergizes with Temozolomide for Antimyeloma Effects
por: Shen, Hong-Yuan, et al.
Publicado: (2022)

First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumours
por: Martin-Liberal, Juan, et al.
Publicado: (2020)

CEP19 cooperates with FOP and CEP350 to drive early steps in the ciliogenesis programme
por: Mojarad, Bahareh A., et al.
Publicado: (2017)

A Phase 1 study for safety and pharmacokinetics of BIO101 (20‐hydroxyecdysone) in healthy young and older adults
por: Dioh, Waly, et al.
Publicado: (2023)

SPDR-01 INHIBITION OF HOMOLOGOUS RECOMBINATION, PARP INHIBITOR, OR DIANHYDROGALACTITOL OVERCOMES TEMOZOLOMIDE-RESISTANCE IN GLIOMA CELLS
por: Ohba, Shigeo, et al.
Publicado: (2019)

Soft QCD and CEP at LHCb
por: Giubega, Lavinia-Elena
Publicado: (2019)

Aggresome assembly at the centrosome is driven by CP110–CEP97–CEP290 and centriolar satellites
por: Prosser, Suzanna L., et al.
Publicado: (2022)

A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study
por: Diéras, Véronique, et al.
Publicado: (2016)

Cep126 is required for pericentriolar satellite localisation to the centrosome and for primary cilium formation
por: Bonavita, Raffaella, et al.
Publicado: (2014)

A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastoma
por: Fine, Howard, et al.
Publicado: (2023)

Root-Knot-Nematode-Encoded CEPs Increase Nitrogen Assimilation
por: Mishra, Shova, et al.
Publicado: (2023)

The centriolar satellite proteins Cep72 and Cep290 interact and are required for recruitment of BBS proteins to the cilium
por: Stowe, Timothy R., et al.
Publicado: (2012)

The APC/C targets the Cep152–Cep63 complex at the centrosome to regulate mitotic spindle assembly
por: Tischer, Thomas, et al.
Publicado: (2022)

Targeting CD47-SIRPa axis shows potent preclinical anti-tumor activity as monotherapy and synergizes with PARP inhibition
por: Al-Sudani, Hussein, et al.
Publicado: (2023)

Effectiveness of dose-escalated topiramate monotherapy and add-on therapy in neurosurgery-related epilepsy: A prospective study
por: Liu, Yu-Tse, et al.
Publicado: (2020)

Nuclear Export Inhibitor KPT-8602 Synergizes with PARP Inhibitors in Escalating Apoptosis in Castration Resistant Cancer Cells
por: Uddin, Md. Hafiz, et al.
Publicado: (2021)

Central Exclusive Production (CEP) at LHCb
por: Mcnulty, Ronan
Publicado: (2018)

PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O(6)-methylguanine DNA damage in glioblastoma
por: Wu, Shaofang, et al.
Publicado: (2021)

The role of KDEL-tailed cysteine endopeptidases of Arabidopsis (AtCEP2 and AtCEP1) in root development
por: Höwing, Timo, et al.
Publicado: (2018)

Cep57 and Cep57L1 maintain centriole engagement in interphase to ensure centriole duplication cycle
por: Ito, Kei K., et al.
Publicado: (2021)

Diversification of the C-TERMINALLY ENCODED PEPTIDE (CEP) gene family in angiosperms, and evolution of plant-family specific CEP genes
por: Ogilvie, Huw A, et al.
Publicado: (2014)

CEP78 functions downstream of CEP350 to control biogenesis of primary cilia by negatively regulating CP110 levels
por: Gonçalves, André Brás, et al.
Publicado: (2021)

Alternative splicing in CEP290 mutant cats results in a milder phenotype than LCA (CEP290) patients
por: Minella, Andrea L., et al.
Publicado: (2022)

Phase I dose-escalation study of procaspase-activating compound-1 in combination with temozolomide in patients with recurrent high-grade astrocytomas
por: Holdhoff, Matthias, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mf1mgv47blqa6klg3090611k2p